Is Fidaxomicin Worth the Cost? An Economic Analysis
Open Access
- 23 May 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (4), 555-561
- https://doi.org/10.1093/cid/cit346
Abstract
Background. In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined. Methods. We developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results. Results. The incremental cost-effectiveness ratio for fidaxomicin based on screening given current conditions was >$43.7 million per quality-adjusted life-year and using only fidaxomicin was dominated (ie, more costly and less effective) by the other 2 treatment strategies explored. The fidaxomicin strategy tended to remain dominated, even at lower costs. With approximately 50% of CDI due to the NAP1/BI/027 strain, a course of fidaxomicin would need to cost ≤$150 to be cost-effective in the treatment of all CDI cases and between $160 and $400 to be cost-effective for those with a non-NAP1/BI/027 strain (ie, treatment based on strain typing). Conclusions. Given the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin.Keywords
This publication has 37 references indexed in Scilit:
- Burden of Clostridium difficile on the Healthcare SystemClinical Infectious Diseases, 2012
- The potential economic value of screening hospital admissions for Clostridium difficileEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- The economic burden of Clostridium difficileClinical Microbiology & Infection, 2012
- Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistencyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011
- Comparison of Strain Typing Results for Clostridium difficile Isolates from North AmericaJournal of Clinical Microbiology, 2011
- Update on Clostridium difficile infectionCurrent Opinion in Gastroenterology, 2011
- Clostridium difficile InfectionThe American Journal of the Medical Sciences, 2010
- Clostridium difficileinfection: update on emerging antibiotic treatment options and antibiotic resistanceExpert Review of Anti-infective Therapy, 2010
- Clinical Severity of Clostridium difficile PCR Ribotype 027: A Case-Case StudyPLOS ONE, 2008
- A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease SeverityClinical Infectious Diseases, 2007